ADR Ontology |
ADR Term |
Myasthenia gravis |
ADR ID |
BADD_A02913 |
ADR Hierarchy |
|
Description |
A disorder characterized by weakness and rapid fatigue of any of the skeletal muscles. [CTCAE] A disorder of neuromuscular transmission characterized by weakness of cranial and skeletal muscles. Autoantibodies directed against acetylcholine receptors damage the motor endplate portion of the NEUROMUSCULAR JUNCTION, impairing the transmission of impulses to skeletal muscles. Clinical manifestations may include diplopia, ptosis, and weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles. THYMOMA is commonly associated with this condition. (Adams et al., Principles of Neurology, 6th ed, p1459) [MeSH] |
MedDRA Code |
10028417 |
MeSH ID |
D009157
|
ADR Severity Grade (FAERS)
|
|
ADR Severity Grade (CTCAE)
|
|
Synonym |
Myasthenia gravis | Myasthenia gravis aggravated | Myasthenia gravis paralytica | Myasthenia Gravis | Myasthenia Gravis, Ocular | Ocular Myasthenia Gravis | Myasthenia Gravis, Generalized | Generalized Myasthenia Gravis |
|
|
ADR Related Proteins |
Protein Name |
UniProt AC |
TTD Target ID |
Not Available | Not Available | Not Available |
|
Drugs Leading to the ADR |
|